Provides health care information technology solutions and tech-enabled services. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
No real growth (3% a year).
The gap is $993.8M. In times of high interest rates, a gap like that can squeeze a company.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
It pays out $0.98 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales grew only 3% a year on average. At this size, speeding back up is not easy.
The price action doesn’t yet back an upward turn.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.